泛耐药鲍曼不动杆菌耐药性和同源性分析

doi:10.3969/j.issn.1673-8640.2013.04.006

检验医学 ›› 2013, Vol. 28 ›› Issue (3): 194-198.DOI: 10.3969/j.issn.1673-8640.2013.04.006

泛耐药鲍曼不动杆菌耐药性和同源性分析

赵付菊¹,刘华勇²,周丽芳³,方毅³,庞立峰³,刘文健³,赵虎⁴

1.复旦大学附属华东医院检验科，上海 200040；2.复旦大学上海医学院教育部/卫生部医学分子病毒学重点实验室，上海 200032

收稿日期:2012-09-20 修回日期:2012-11-30 出版日期:2013-03-30 发布日期:2013-03-14
通讯作者: 赵虎，联系电话：021-62483180-20847。
作者简介:赵付菊，女，1985年生，硕士生，主要从事临床微生物学研究。
基金资助:
上海市科学技术委员会资助项目（10ZR1410600）

Analysis on the drug resistance and homology of pandrug-resistant Acinetobacter baumannii

1. Department of Clinical Laboratory，Huadong Hospital，Fudan University，Shanghai 200040，China; 2. Key Laboratory of Medical Molecular Virology of Ministry of Education and Ministry of Health，Shanghai Medical College of Fudan University，Shanghai 200032，China

Received:2012-09-20 Revised:2012-11-30 Online:2013-03-30 Published:2013-03-14
Contact: Hu ZHAO
Supported by:
Scince and Technology Commission of Shanghai Municipality

摘要/Abstract

摘要： 目的　分析泛耐药鲍曼不动杆菌（PDRAB）的耐药性、同源性及感染病例的临床特征和治疗情况，为指导临床合理用药、控制感染提供依据。方法　收集临床分离自住院患者的鲍曼不动杆菌，用法国生物梅里埃VITEK-2 Compact全自动细菌分析仪及药敏纸片法分析菌株耐药性。选取PDRAB感染的病例，用回顾性统计分析方法分析PDRAB感染病例的临床特征及疗效转归；用微量板半定量法检测PDRAB 菌株的生物膜形成能力；用脉冲场凝胶电泳法分析PDRAB 菌株的同源性。结果　共收集鲍曼不动杆菌138株，其中PDRAB 菌株11株，占7.97%；选取PDRAB感染的病例10例，其中呼吸重症监护室7例（70%）、普外科2例（20%）、普通重症监护室1例（10%）。10株PDRAB对多黏菌素B敏感率为100%，对目前所有常规的抗菌药物耐药率为100%。138株鲍曼不动杆菌菌株中生物膜阳性7株（5.07%），其中PDRAB 2株、非PDRAB 5株。10株PDRAB 菌株共分为7型(A、B、C、D、E、F、G)，其中D和E型中的2株菌株的同源性高，其余为散发株。结论　呼吸重症监护病房泛耐药现象严重，长期广谱抗菌药物的使用、侵入性诊疗，合并多种基础疾病与感染发生密切相关，多种抗菌药物联合使用对控制PDRAB 感染有一定疗效。PDRAB耐药机制复杂，应以呼吸重症监护室为防控重点，同时加强对生物膜阳性菌株所分布的病区的耐药性监测。

关键词: 鲍曼不动杆菌, 泛耐药, 危险因素, 生物膜, 脉冲场凝胶电泳, 医院感染

Abstract: Objective　To investigate the drug resistance and homology of pandrug-resistant Acinetobacter baumannii (PDRAB) and analyze the clinical characteristics and outcome of its infection，so as to provide reference for the clinical reasonable medication and the prevention of the infection. Methods　The drug resistance of Acinetobacter baumannii from inpatients of the hospital was determined by automatic microbial identification system of BioMerieux VITEK-2 Compact and Kirby-Bauer method. Retrospective investigation was performed on the clinical characteristics and therapeutic efficacy turnover of the patients with PDRAB infection. A semiquantitative plate assay was used to test the biofilm-forming ability of PDRAB. The homology of PDRAB was detected by pulsed-field gel electrophoresis. Results　A total of 138 Acinetobacter baumannii were isolated，among which 11 (7.97%) isolates were PDRAB. A total of 10 in patients with PDRAB infection were enrolled in the study. The PDRAB infection occurred most frequently in respiratory intensive care unit，7 (70%) isolates were from respiratory intensive care unit，2 (20%) isolates were from surgical unit，and 1 (10%) isolate was from intensive care unit. The polymyxin sensitivity of all 10 PDRAB was 100%，but they were resistant to all other antibiotics in routine clinical use，and the resistance rate was 100%. There were 7 (5.07%) biofilm-positive isolates among the 138 Acinetobacter baumannii，2 isolates were PDRAB，and 5 isolates were non-PDRAB. All of 10 PDRAB were classified into 7 pulsotypes（A，B，C，D，E，F and G），the homology of 2 isolates of Pulsotype D and Pulsotype E was high，and the others were sporadic isolates. Conclusions　Pandrug-resistance is serious in respiratory intensive care unit of the hospital. Pandrug-resistance is closely related to long-term use of broad-spectrum antibiotics，invasive treatment，and patients with multiple underlying diseases. A variety of antimicrobial agents used in combination use have a certain effect on the control of PDRAB infection. It is necessary to strengthen the monitoring of drug resistant and biofilm-positive isolates，especially in respiratory intensive care unit.

Key words: Acinetobacter baumannii, Pandrug-resistance, Risk factor, Biofilm, Pulsed-field gel electrophoresis, Nosocomial infection

赵付菊1，刘华勇2，周丽芳1，方毅1，庞立峰1，刘文健1，赵虎1. 泛耐药鲍曼不动杆菌耐药性和同源性分析[J]. 检验医学, 2013, 28(3): 194-198.

ZHAO Fuju 1，LIU Huayong 2，ZHOU Lifang 1，FANG Yi 1，PANG Lifeng 1，LIU Wenjian 1，ZHAO Hu 1. Analysis on the drug resistance and homology of pandrug-resistant Acinetobacter baumannii[J]. , 2013, 28(3): 194-198.

参考文献

[1]Roca I，Espinal P，Vila-Farrés X，et al. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace[J]. Front Microbiol，2012，3: 1-148.
[2]Fournier PE，Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities[J]. Clin Infect Dis，2006，42(5): 692-699.
[3]Morgan DJ，Weisenberg SA，Augenbraun MH，et al. Multidrug-resistant Acinetobacter baumannii in New York City-10 years into the epidemic[J]. Infect Control Hosp Epidemiol，2009，30(2): 196-197.
[4]Tomaras AP，Dorsey CW，Edelmann RE，et al. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system[J]. Microbiology，2003，149(Pt 12): 3473-3484.
[5]Vincent J，Rello J，Marshall J，et al. International study of the prevalence and outcomes of infection in intensive care units[J]. JAMA，2009，302(21): 2323-2329.
[6]Le Hello S，Falcot V，Lacassin F，et al. Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia，South Pacific[J]. Scand J Infect Dis，2010，42(11-12): 821-826.
[7]孙树梅，王茵茵，姚翠军，等.泛耐药鲍曼不动杆菌感染的临床特征及抗感染治疗分析[J]. 南方医科大学学报，2010，30(10): 2351-2353.
[8]Manikal VM，Landman D，Saurina G，et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn，New York: citywide prevalence，interinstitutional spread，and relation to antibiotic usage[J]. Clin Infect Dis，2000，31(1): 101-106. 
[9]Munoz-Price LS，Weinstein RA. Acinetobacter infection[J]. N Engl J Med，2008，358(12): 1271-1281.
[10]杜坤，应春妹，汪雅萍，等.上海地区四家医院鲍曼不动杆菌产β-内酰胺酶研究[J].检验医学，2012，27（2）：103-109.
[11]侯盼飞，杜坤，应春妹，等.亚胺培南耐药鲍曼不动杆菌外排泵机制研究[J].检验医学，2012，27（2）：95-98.
[12]罗柳林，应春妹，倪培华，等.耐碳青霉烯类抗菌药物鲍曼不动杆菌膜蛋白机制研究[J].检验医学，2010，25（4）：304-308.
[13]Espinal P，Martí S，Vila J. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces [J]. J Hosp Infect，2012，80(1): 56-60. 
[14]王丽丽，徐建国.脉冲场凝胶电泳技术（PFGE）在分子分型中的应用现状[J]. 疾病监测，2006，21(5): 276-279.
[15]张丽，杨文航，肖盟，等.2010年度卫生部全国细菌耐药监测网报告：ICU来源细菌耐药性监测[J].中华医院感染学杂志，2012，22(1): 34-38.

泛耐药鲍曼不动杆菌耐药性和同源性分析

Analysis on the drug resistance and homology of pandrug-resistant Acinetobacter baumannii

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	伏艺, 杨雪松, 金立钢, 翟红礼, 金小玲. sd-LDL-C与ACS患者远期不良心血管事件发生的相关性[J]. 检验医学, 2023, 38(9): 878-883.
[2]	马冬梅, 蒋东葵, 相晓波, 李世亮. 板蓝根等4种中药单用和与西药联用对广泛耐药鲍曼不动杆菌的抑菌作用[J]. 检验医学, 2023, 38(5): 441-445.
[3]	王洪玲, 刘梦娜, 白萍, 廖焕金. AML患者异基因造血干细胞移植后复发危险因素分析[J]. 检验医学, 2023, 38(12): 1160-1166.
[4]	柴凤霞, 唐丽华, 王磊. Lp-PLA2和hs-CRP在动脉粥样硬化评估中的应用[J]. 检验医学, 2022, 37(8): 798-799.
[5]	孙伟, 夏帅, 樊玉健, 马立艳. 不同基因型别纹带棒状杆菌耐药特点和生物膜形成能力分析[J]. 检验医学, 2022, 37(6): 505-509.
[6]	潘允琪, 李运改, 王坚镪, 吴琼, 汤瑾. 复发性尿路感染患者致病性大肠埃希菌分子分型、毒力基因及药物敏感性分析[J]. 检验医学, 2022, 37(2): 141-145.
[7]	乐江漫, 李天园, 谭美玉, 王亚捷, 周丽达, 殳洁, 武娇祥, 孙寒晓, 宣彬彬, 蔡徐山, 盛慧明. 血浆氧化三甲胺水平与妊娠糖尿病的相关性[J]. 检验医学, 2021, 36(8): 795-799.
[8]	薛娜丽, 何艳佩, 范德平, 黄秋兰. 亚胺培南、美罗培南、比阿培南联合头孢哌酮-舒巴坦对医院获得性MRAB的抗菌效果分析[J]. 检验医学, 2021, 36(8): 814-817.
[9]	张冠怡, 姚冬婷, 王健, 胡晓波. 光滑念珠菌耐药机制及中西药治疗光滑念珠菌感染研究进展[J]. 检验医学, 2021, 36(7): 761-765.
[10]	黄晓峰, 范雪明, 姚天悦, 袁文华, 赵智赟, 宋云霄. 外周血红细胞平均分布宽度与前列腺癌的相关性研究[J]. 检验医学, 2021, 36(6): 590-595.
[11]	周燕霞, 金东芳. 单宁酸抑制肺炎克雷伯菌生物膜形成的作用及其机制[J]. 检验医学, 2021, 36(10): 1070-1073.
[12]	李婵婵, 王茹, 罗文英. 铜绿假单胞菌转录因子PsrA全局调控研究进展[J]. 检验医学, 2020, 35(8): 832-836.
[13]	张秋, 李杰, 王猛, 王毅, 杨波, 胡征. 嗜肺军团菌快速检测胶体金试纸的研制[J]. 检验医学, 2020, 35(7): 726-733.
[14]	钟峰, 冯艺, 张晶晶, 许岩, 方咏梅, 陶秀彬, 吴竞. 替加环素联合亚胺培南对黏液型铜绿假单胞菌的体外抗菌活性及生物膜抑制作用分析[J]. 检验医学, 2020, 35(6): 519-523.
[15]	王军杰, 姚宗会, 马冰, 李轶, 闫文娟, 王山梅, 马琼, 袁有华. 碳青霉烯类耐药肺炎克雷伯菌致血流感染危险因素及预后分析[J]. 检验医学, 2020, 35(3): 195-199.